A Phase 3 interventional study of Bevacizumab and HD204 in Lung Cancer and Non-small Cell Lung Cancer, sponsored by Prestige Biopharma Limited. Active, not recruiting at 18 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-31.
Sponsored by Prestige Biopharma Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Carcinoma, Non-Small-Cell Lung with a site in Georgia — 9 open to participants now, 31 under way, 14 of them phase 3. Carcinoma, Non-Small-Cell Lung · Georgia.
Among the 54 studies in Carcinoma, Non-Small-Cell Lung with a site in Georgia, this one is the 14th largest by enrollment, is one of 4 that started in 2019, is one of 25 in phase 3, reaches primary completion later than 0 of the 30 other live ones, and was the 11th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →9 of the 54 studies in Carcinoma, Non-Small-Cell Lung with a site in Georgia are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Georgia, Australia, Poland and 2 more countries
Ages 18+
IDEAYA Biosciences · Sites in Georgia, United States, Spain
Ages 18+
AstraZeneca · Sites in Georgia, United States, Belgium and 17 more countries
Ages 18+
AstraZeneca · Sites in Georgia, United States, Argentina and 24 more countries
Ages 18+
Jazz Pharmaceuticals · Sites in Georgia, United States, Korea, Republic of and 1 more country
Ages 18+
A study can be open while its sites in Georgia have not opened yet or have stopped. Only those recruiting at a site in Georgia →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 24 · Phase 3 29
First in 2008; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 650 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 222 across the 54 interventional studies. Of the 22 that completed or were terminated, 14 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 54 have an industry lead sponsor. The 10 most frequent:
Prestige Biopharma Limited is the lead sponsor of 6 studies on the registry; none are open to participants now.
Prestige Biopharma Limited has 1 study filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
12 of the studies in Carcinoma, Non-Small-Cell Lung with a site in Georgia that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06430866Phase 3AmgenPharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) | 2026-12-14 |
| NCT07162883Phase 3Qilu Pharmaceutical Co., Ltd.Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | 2026-12-31 |
| NCT06939595Phase 3CelltrionA Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer | 2027-02 |
| NCT06726265Phase 3Immutep S.A.S.Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) | 2027-06 |
| NCT05785767Phase 3Regeneron PharmaceuticalsA Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | 2027-09-28 |
Add all 12 to your calendar (.ics) → With an account.
Among the 54 studies in Carcinoma, Non-Small-Cell Lung with a site in Georgia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In the SAMSON-2 study, the proposed biosimilar HD204 will be compared to its reference product EU-licensed Avastin®. The aim of the study is to demonstrate equivalence of HD204 and EU-licensed Avastin® in terms of efficacy, safety, pharmacokinetics and immunogenicity.
This is a randomised, double-blind, parallel group, equivalence, multicentre Phase III study in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC).
Standard efficacy parameters, safety profiles, pharmacokinetics and immunogenicity will be compared between HD204 and bevacizumab.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
This study's enrollment of 650 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Prestige Biopharma Limited is the lead sponsor of 6 studies on the registry; none are open to participants now.
Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HD204 + Carboplatin/Paclitaxel
Drug: HD204 · Drug: Carboplatin · Drug: Paclitaxel
Avastin® + Carboplatin/Paclitaxel
Drug: Bevacizumab · Drug: Carboplatin · Drug: Paclitaxel
15 mg/kg IV every 3 weeks on Day 1
Also known as: Avastin
15 mg/kg IV every 3 weeks on Day 1
Also known as: Bevacizumab
Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
Also known as: Taxol
Overall Response Rate (ORR) at Week 18
Percent patients within each treatment group who achieved complete response (CR) or partial response (PR) by the time of the Week 18 efficacy analysis in accordance with the RECIST 1.1. as assessed by CIR.
Time frame: 18 weeks from randomization
ORR at Week 6
Response at Week 6 will be evaluated by CIR to show the pattern of response
Time frame: 6 weeks from randomization
ORR at Week 12
Response at Week 12 will be evaluated by CIR to show the pattern of response
Time frame: 12 weeks from randomization
ORR at Week 18 adjusted on dose intensity
To compare ORR at Week 18 adjusted on dose intensity between treatment groups
Time frame: 18 weeks from randomization
Duration of Response
DoR in subjects with response from documented tumour response until disease progression up to 12 months from randomisation of the last subject
Time frame: from documented tumour response until disease progression up to 12 months from randomisation
Progression Free Survival
PFS from the date of randomisation to the date of disease progression or death up to 12 months from randomisation
Time frame: From the date of randomisation to the date of disease progression or death up to 12 months from randomisation of the last subject
Overall Survival (OS)
OS defined as the time from Day 1 of therapy until death from any cause
Time frame: From the date of randomisation to the date of death up to 12 months from randomisation
Change in tumour burden from baseline
Measured by the sum of longest diameters (SLD) of the target lesions
Time frame: Up to 52 weeks from baseline
Incidence of Treatment-related Adverse Events using CTCAE v5.0
After the end of treatment (EOT) visit, SAEs should be reported to the Sponsor if the Investigator becomes aware of them.
Time frame: From signing the ICF until 1 month after the last administration of treatment, i.e., up to 52 weeks
Anti-Drug Antibodies (Immunogenicity)
Incidence of anti-drug (bevacizumab) antibodies (ADA)
Time frame: Up to 52 weeks (at Baseline; end of Cycle 4 [pre-dose in cycle 5]; end of Cycle 7 [pre-dose in cycle 8]; and at EOT)
Neutralizing Antibodies (Immunogenicity)
Incidence of anti-drug (bevacizumab) antibodies (ADA) - neutralizing antibodies (NAb)
Time frame: Up to 52 weeks (at Baseline; end of Cycle 4 [predose in cycle 5]; end of Cycle 7 [predose in cycle 8]; and at EOT)
Trough Level [Ctrough] (Pharmacokinetics)
Concentration observed 19 to 23 days after study drug administration
Time frame: Up to 52 weeks (end of Cycle 1 [predose of Cycle 2], end of Cycle 3 [predose of Cycle 4], end of Cycle 5 [predose of Cycle 6] and EOT)
Maximum Plasma Concentration [Cmax] (Pharmacokinetics)
Cmax at selected cycles
Time frame: Up to 21 weeks (Cycle 2 ,4 and 6. Each cycle is 21 days.)
Area under the concentration-time curve from 0 hr to time t [AUC0-t] (Pharmacokinetics)
AUC0-t at selected cycles
Time frame: Up to 21 weeks (Cycle 2 ,4 and 6. Each cycle is 21 days.)
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Nov 2019 to primary completion in Jul 2024, 55 months.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 55 months is above that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →
Prestige Biopharma Limited